The purpose of this clinical trial is to evaluate the safety and efficacy of a food supplement OMNIA compared to a placebo in reducing the body fat mass in 70 overweight subjects during 12 weeks treatment.
Overweight and obesity represent a serious public health issue. These conditions are characterized by an abnormal or excessive accumulation of body fat mass and they are related to an increase risk of developing chronic diseases such as cardiovascular, diabetes, arthrosis and certain kind of cancer (breast; colon). It's thus necessary to find new products able to counteract both overweight and obesity. Omnia is a food supplement based on a Phaseolus vulgaris extract. It has pancreatic amylase inhibition properties. In the following clinical trial, OMNIA will be administrated to a group of overweight subjects in order to evaluate its efficacy on reducing the body fat mass. Its action will be compared to a placebo administered to a second group of overweight volunteers with the same modalities as OMNIA.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
86
Reduction of body fat mass loss measured by DEXA (Dual-energy X-ray absorptiometry)
Time frame: 12 weeks
change from baseline in Body Mass Index (BMI)
Time frame: 6, 12 weeks
change from baseline on the ratio fat/lean body mass measured by DEXA
Time frame: 12 weeks
change from baseline on weight
Time frame: 6, 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.